Orthofix achieved Q4 revenue of $219.9 million, showing 2% growth, while significantly reducing its net loss to $2.2 million. The company demonstrated strong operational progress with robust free cash flow of $16.8 million in the quarter and double-digit growth in its Global Spine Fixation business, despite the decision to discontinue the M6 product lines.

Orthofix delivered a strong third quarter in 2025, achieving $205.6 million in net sales and a significant increase in non-GAAP pro forma adjusted EBITDA to $24.6 million. The company reported a net loss of $(22.8) million, or $(0.57) per share, but demonstrated consistent adjusted EBITDA margin expansion for the seventh consecutive quarter and positive free cash flow.

Orthofix reported net sales of $203.1 million for the second quarter of 2025, a 2.3% increase year-over-year. The company achieved a net loss of $(14.1) million, or $(0.36) per share, and reported positive free cash flow of $4.5 million. Pro forma adjusted EBITDA increased by 24.1% to $20.6 million, with margin expansion for the sixth consecutive quarter.

Orthofix reported first quarter 2025 net sales of $193.6 million, an increase of 2.7% on a reported basis compared to Q1 2024. The company experienced a net loss of $(53.1) million, or $(1.35) per share, and a non-GAAP pro forma adjusted EBITDA of $11.4 million.

Orthofix reported record fourth quarter net sales of $215.7 million, an increase of 8% compared to the fourth quarter of 2023. The company's net loss was $(29.1) million, with a non-GAAP adjusted EBITDA of $23.9 million.

Orthofix's Q3 2024 net sales increased by 7% to $196.6 million. The company reported a net loss of $(27.4) million, with Non-GAAP adjusted EBITDA of $19.2 million. Free cash flow was $5.9 million. The company reiterated its full-year 2024 financial guidance and introduced new three-year financial targets.

Orthofix reported a 6% increase in net sales, reaching $198.6 million in Q2 2024. The company experienced growth across all business segments, particularly in Bone Growth Therapies and U.S. Spine Fixation, both growing at 12%. Despite the revenue growth, Orthofix reported a net loss of $(33.4) million, but improved non-GAAP adjusted EBITDA to $16.6 million. The company raised its full-year net sales and adjusted EBITDA guidance.

Orthofix reported a 7.7% increase in net sales to $188.6 million. Net loss was $36 million, with an EPS of $(0.95). Non-GAAP adjusted EBITDA was $7.7 million, representing a 220 basis point expansion over the prior year period. The company raised the midpoint of its full-year net sales guidance, narrowing the range to $790.0-$795.0 million.

Orthofix reported Q4 2023 net sales of $200.4 million, a 64% increase on a reported basis and 7% on a pro forma constant currency basis. The net loss was $22 million, with an EPS of $(0.59). Non-GAAP Adjusted EBITDA was $20 million, representing a 96% growth over Q4 2022.

Orthofix reported net sales of $184.0 million, a 61% increase on a reported basis and an 8% increase on a pro forma basis. EPS was $(0.77), and adjusted EPS was $0.07. The company saw strong growth across multiple business segments and product lines and is focused on driving shareholder value via profitable growth and merger synergy realization.

Orthofix reported net sales of $187.0 million, EPS of $(1.07), and adjusted EPS of $0.02 for the second quarter of 2023. The company experienced growth in Bone Growth Therapies and U.S. spinal implants, biologics, and enabling technologies sales.

Orthofix reported a strong first quarter with a 65% increase in net sales to $175.2 million. The company saw growth across all channels, driven by cross-selling strategies and new product launches. However, the company reported a net loss of $(60.9) million, or $(1.71) per share and an adjusted net loss of $(3.6) million, or $(0.10) per share.

Orthofix reported Q4 net sales of $122.2 million, a decrease of 2% year-over-year, while SeaSpine reported net sales of $63.4 million, a 14% increase year-over-year. Both companies highlighted growth in key segments and are now focused on integration following their merger on January 5, 2023.

Orthofix reported a 1% increase in net sales to $114.0 million, with a GAAP EPS of ($0.53) and an adjusted EPS of $0.13. The company saw growth in Global Orthopedics, Biologics, and Bone Growth Therapies, driven by new product innovation and commercial channel execution.

Orthofix reported Q2 2022 net sales of $118.1 million, a decrease of 3% on a reported basis but flat on a constant currency basis. GAAP EPS was $0.12, and adjusted EPS was $0.08. The company is maintaining full-year revenue guidance of $455 to $465 million.

Orthofix Medical Inc. reported first quarter 2022 financial results with net sales of $106.4 million, EPS of $(0.22), and adjusted EPS of $(0.10). The company reaffirmed its 2022 guidance.

Orthofix reported a 6% increase in net sales for the fourth quarter of 2021, driven by double-digit growth in Global Spinal Implants and Orthopedics. Despite headwinds, the company delivered double-digit revenue growth and advanced strategic initiatives. The company anticipates accelerating top line growth in 2022 and beyond.

Orthofix Medical Inc. reported a 1.3% increase in net sales to $112 million for the quarter ended September 30, 2021. The company's EPS was $(0.11), and adjusted EPS was $0.10.

Orthofix Medical Inc. reported a strong second quarter with net sales of $121 million, a 66% increase compared to the prior year. EPS was $0.12, and adjusted EPS was $0.32. The company is raising its full year 2021 revenue and adjusted EBITDA guidance.

Orthofix Medical Inc. reported net sales of $105.6 million, EPS of $(0.30), and adjusted EPS of $0.17 for the quarter ended March 31, 2021. The company highlighted the positive revenue impact from new product introductions and the development of its U.S. commercial channel.

Orthofix reported Q4 net sales of $117.6 million, EPS of $(0.48), and adjusted EPS of $0.44. The company drove revenue close to 2019 levels while solidifying its organization amidst global elective procedure restrictions. They are shifting their transformation to execution phase, aiming for growth and high-value solutions.

Orthofix reported a net sales of $111.0 million, EPS of $0.24, and adjusted EPS of $0.31 for Q3 2020. The U.S. spinal implants business grew 19% over the third quarter of 2019.

Orthofix Medical Inc. reported a 37% decrease in net sales to $73.1 million for the second quarter of 2020, with a net loss of ($0.96) per share. However, the company saw sequential revenue rebound in May and June and record motion preservation sales in the U.S.

Orthofix Medical Inc. reported a decrease in net sales by 3.9% to $104.8 million for the first quarter ended March 31, 2020. However, the company's diluted earnings per share (EPS) was $1.32, and adjusted EPS was $0.09. The company proactively responded to COVID-19 challenges to ensure balance sheet and capital liquidity.

Orthofix Medical Inc. reported net sales of $121.5 million, EPS of $0.60, and adjusted EPS of $0.51 for the fourth quarter of 2019.